ADV6209 is an oral liquid solution developed by Advicenne for moderate sedation.
ADV6209 has been specially designed for children to significantly reduce their anxiety and to improve their immobility when they undertake stressful or painful medical, therapeutic or diagnostic procedures. It is the the only oral midazolam in liquid form which would be suitable and indicated for children older than 6 months approved.
Marketing Authorisation was granted on September 12th 2018.
The product was originally developed in collaboration with Amiens’s public hospital (University Hospital).
In March 2016, Advicenne sold ADV6209 to Primex Pharmaceuticals, a Swiss company, in a global deal worth [several tens of millions of euros give a range or estimate] with a significant upfront payment and subsequent milestones and royalties.
Advicenne has been commercializing Likozam®, a product in-licensed from Rosemont, in France since February 2016. Likozam® is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy.
Likozam® can be used to treat partial and generalized chronic refractory epilepsy in children and adults. It is the only product available on the market for refractory epilepsy in a liquid form that is suitable and indicated for children six years old or younger and people with swallowing difficulties.
Advicenne has been commercializing Levidcen®, a product in-licensed from Desitin GmbH, in France since October 2015. Levidcen® is used to address the unmet medical need of epileptic patients with partial onset seizures.
Levidcen® is a granulated (2 mm) formulation of levetiracetam designed to treat epilepsy in children and adults. Levidcen® is tasteless and has been specifically adapted for children and patients with swallowing difficulties. Other formulations of levetiracetam are either liquids with a horrible taste which may reduce patient compliance or large tablets of approximately 13-19mm which are not suitable for patients with swallowing difficulties.